Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma

We report the largest published US cohort of patients treated with 106Ru plaque brachytherapy for uveal melanoma. Tumor control was excellent, and toxicity was acceptably low. These data support the reintroduction of 106Ru into clinical practice for ocular melanoma.